Effect of Accelerated RTH in Squamous Cell Carcinoma in Head and Neck
Retrospective Study of Effect of Accelerated Radiation Therapy , Six Fractions Per Week , for Squamous Cell Carcinoma of Head and Neck.
1 other identifier
observational
100
0 countries
N/A
Brief Summary
Evaluation of the efficacy of the accelerated radiotherapy in squamous cell carcinoma of head and neck
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Mar 2022
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
March 14, 2022
CompletedStudy Start
First participant enrolled
March 20, 2022
CompletedFirst Posted
Study publicly available on registry
March 23, 2022
CompletedPrimary Completion
Last participant's last visit for primary outcome
March 20, 2023
CompletedStudy Completion
Last participant's last visit for all outcomes
December 20, 2023
CompletedMarch 23, 2022
March 1, 2022
1 year
March 14, 2022
March 14, 2022
Conditions
Outcome Measures
Primary Outcomes (1)
Determine progression-free survival rate
Determine the toxicity and loco-regional control by using accelerated RTH in squamous cell carcinoma in head and neck
Baseline
Eligibility Criteria
-Patients of (18 up to 75 years of age)
You may qualify if:
- Patients of (18 up to 75 years of age)
- Performance status of 0-2 according to ECOG scale.
- Patients with no prior chemotherapy, radiotherapy or surgery except for biopsy.
You may not qualify if:
- Patients with previous irradiation to head and neck.
- Pregnant or lactating women.
- Patients with impaired heart or lung diseases.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Related Publications (4)
Ferlay J, Colombet M, Soerjomataram I, Mathers C, Parkin DM, Pineros M, Znaor A, Bray F. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer. 2019 Apr 15;144(8):1941-1953. doi: 10.1002/ijc.31937. Epub 2018 Dec 6.
PMID: 30350310RESULTWindon MJ, D'Souza G, Rettig EM, Westra WH, van Zante A, Wang SJ, Ryan WR, Mydlarz WK, Ha PK, Miles BA, Koch W, Gourin C, Eisele DW, Fakhry C. Increasing prevalence of human papillomavirus-positive oropharyngeal cancers among older adults. Cancer. 2018 Jul 15;124(14):2993-2999. doi: 10.1002/cncr.31385. Epub 2018 Apr 30.
PMID: 29710393RESULTBlot WJ, McLaughlin JK, Winn DM, Austin DF, Greenberg RS, Preston-Martin S, Bernstein L, Schoenberg JB, Stemhagen A, Fraumeni JF Jr. Smoking and drinking in relation to oral and pharyngeal cancer. Cancer Res. 1988 Jun 1;48(11):3282-7.
PMID: 3365707RESULTJohnson DE, Burtness B, Leemans CR, Lui VWY, Bauman JE, Grandis JR. Head and neck squamous cell carcinoma. Nat Rev Dis Primers. 2020 Nov 26;6(1):92. doi: 10.1038/s41572-020-00224-3.
PMID: 33243986RESULT
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
Mostafa El-sayed Abd Elwanis
Assiut University
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- CASE CONTROL
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Doctor
Study Record Dates
First Submitted
March 14, 2022
First Posted
March 23, 2022
Study Start
March 20, 2022
Primary Completion
March 20, 2023
Study Completion
December 20, 2023
Last Updated
March 23, 2022
Record last verified: 2022-03